Abstract: The present invention relates to a method for treating a disease in a subject by modulating an isoform of MKL-1 by administering to said subject a therapeutically effective amount of a modulator of said isoform of MKL1, wherein said isoform of MKL1 comprises the amino acid sequence of SEQ ID NO:1.

Abstract: The present invention relates to a method for treating cancer, for instance brain tumors, in a subject by inhibiting a teneurin by administering to said subject a therapeutically effective amount of a modulator of said teneurin, for example a specific antibody or a siRNA. The present invention also encompasses methods of diagnosing cancer by measuring levels of teneurin.

Abstract: The present invention relates to a method for treating brain cancer in a subject by administering to said subject a therapeutically effective amount of a modulator of the interaction between SPARC related modular calcium binding 1 (SMOC1) and tenascin-C, for example a specific antibody or a siRNA. The present invention also encompasses methods of diagnosing cancer by measuring levels of SMOC1, as well as method of targeted therapy using anti-SMOC1 or tenascin-C antibodies conjugated to therapeutic agents.

Abstract: The present invention relates to a method for treating cancer, for instance brain tumors, in a subject by inhibiting a teneurin by administering to said subject a therapeutically effective amount of a modulator of said teneurin, for example a specific antibody or a siRNA. The present invention also encompasses methods of diagnosing cancer by measuring levels of teneurin.

Abstract: The FNIII13 domain of fibronectin and smaller fragments thereof have a tumour cell proliferation inhibitory effect. Compositions are provided comprising fragments of fibronectin having the FNIII 13 domain and fragments thereof. A system comprising cells exposed to fibronectin and caused to proliferate by the presence of tenascin are used as an in vitro method for screening possible anti-tumour agents. Cell-free systems comprising a fibronectin ligand and tenascin are also employed for screening potential anti-tumour or anti-cancer agents. Test compounds are assayed for the ability to disrupt binding of the fibronectin ligand to tenascin. A further cell-free system additionally includes a syndecan molecule.

Abstract: Tenascin-W. an extracellular matrix molecule that is specifically expressed in metastatic tumours is provided. A system comprising a sample expressing tenascin-W is used as an in vitro method for screening possible anti-tumour agents or for agents that promote osteogenesis.

Abstract: Tenascin-W, an extracellular matrix molecule that is specifically expressed in metastatic tumours is provided. A system comprising a sample expressing tenascin-W is used as an in vitro method for screening possible anti-tumour agents or for agents that promote osteogenesis.

Abstract: The FNIII13 domain of fibronectin and smaller fragments thereof have a tumour cell proliferation inhibitory effect. Compositions are provided comprising fragments of fibronectin having the FNIII 13 domain and fragments thereof. A system comprising cells exposed to fibronectin and caused to proliferate by the presence of tenascin are used as an in vitro method for screening possible anti-tumour agents. Cell-free systems comprising a fibronectin ligand and tenascin are also employed for screening potential anti-tumour or anti-cancer agents. Test compounds are assayed for the ability to disrupt binding of the fibronectin ligand to tenascin. A further cell-free system additionally includes a syndecan molecule.

Abstract: Tenascin-W, an extracellular matrix molecule that is specifically expressed in metastatic tumours is provided. A system comprising a sample expressing tenascin-W is used as an in vitro method for screening possible anti-tumour agents or for agents that promote osteogenesis.

Abstract: The FNIII13 domain of fibronectin and smaller fragments thereof have a tumour cell proliferation inhibitory effect. Compositions are provided comprising fragments of fibronectin having the FNIII 13 domain and fragments thereof. A system comprising cells exposed to fibronectin and caused to proliferate by the presence of tenascin are used as an in vitro method for screening possible anti-tumour agents. Cell-free systems comprising a fibronectin ligand and tenascin are also employed for screening potential anti-tumour or anti-cancer agents. Test compounds are assayed for the ability to disrupt binding of the fibronectin ligand to tenascin. A further cell-free system additionally includes a syndecan molecule.